A word of warning…..
BusinessCann report
FOLLOWING its listing on the London Stock Exchange in May this year Oxford Cannabinoid Technologies (OCT) has seen more than £20m wiped off its market capitalisation.
With its stock price now sitting at 2.43p per share – less than half its listing price – Chief Executive Dr John Lucas says both he and his team have been left ‘shaking their heads’ at the market’s reaction.
The dismal stock performance is a mystery, says Dr Lucas: “No one’s more disappointed about the share performance than myself. Neil (Mahapatra) the Chairman and everybody in the company, we’re all just left shaking our heads because we’re doing everything exactly the same as we said we would do – or better.”
The pharmaceutical company is currently developing four cannabinoid-based compounds aimed at the massive US prescription medicine and pain relief market, worth an estimated $539bn in 2020.
Read full report at https://businesscann.com/uk-cannabis-companys-c-suite-left-shaking-their-heads-in-disbelief-at-companys-poor-stock-performance/
